JP2024502106A5 - - Google Patents

Info

Publication number
JP2024502106A5
JP2024502106A5 JP2023540948A JP2023540948A JP2024502106A5 JP 2024502106 A5 JP2024502106 A5 JP 2024502106A5 JP 2023540948 A JP2023540948 A JP 2023540948A JP 2023540948 A JP2023540948 A JP 2023540948A JP 2024502106 A5 JP2024502106 A5 JP 2024502106A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
linear
branched
alternatively
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502106A (ja
Filing date
Publication date
Priority claimed from IL279972A external-priority patent/IL279972A/en
Application filed filed Critical
Publication of JP2024502106A publication Critical patent/JP2024502106A/ja
Publication of JP2024502106A5 publication Critical patent/JP2024502106A5/ja
Pending legal-status Critical Current

Links

JP2023540948A 2021-01-05 2022-01-05 ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用 Pending JP2024502106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL279972 2021-01-05
IL279972A IL279972A (en) 2021-01-05 2021-01-05 Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
PCT/US2022/011203 WO2022150316A1 (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024502106A JP2024502106A (ja) 2024-01-17
JP2024502106A5 true JP2024502106A5 (https=) 2025-10-07

Family

ID=82358087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540948A Pending JP2024502106A (ja) 2021-01-05 2022-01-05 ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用

Country Status (8)

Country Link
US (1) US20220370431A1 (https=)
EP (1) EP4274569A4 (https=)
JP (1) JP2024502106A (https=)
CN (1) CN116635028A (https=)
AU (1) AU2022205591A1 (https=)
CA (1) CA3199333A1 (https=)
IL (2) IL279972A (https=)
WO (1) WO2022150316A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010761A1 (en) * 2022-07-03 2024-01-11 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer
US12404283B2 (en) 2022-07-03 2025-09-02 Anima Biotech Inc. c-MYC mRNA translation modulators and uses thereof in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4464384A (en) * 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CA2973739A1 (en) * 2015-02-03 2016-03-24 Active Biotech Ab Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as s100-inhibitors
UY37866A (es) * 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
JP7360106B2 (ja) * 2017-12-28 2023-10-12 小胞体ストレス研究所株式会社 ベンゾチアゾイミダゾリル化合物を含有する小胞体ストレス調節剤
CN113710663A (zh) * 2019-02-19 2021-11-26 纳罗医疗公司 Myc家族原癌基因蛋白的调节剂

Similar Documents

Publication Publication Date Title
AU2019348094B2 (en) Isoindoline compound, preparation method, pharmaceutical composition and use thereof
AU2019392231B2 (en) Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
ES2415208T3 (es) Derivados bifenilo con conformación restringida para su uso como inhibidores del virus de la hepatitis C
JP7665518B2 (ja) 化合物及びその使用
JP2024540410A5 (https=)
RU2015110985A (ru) Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний
RU2018129308A (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
CA3255513A1 (en) HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
IL290276B1 (en) Tetracyclic compounds, method for their preparation and use
WO2022236578A1 (en) Exocyclic amino quinazoline derivatives as kras inhibitors
JP2024502106A5 (https=)
JP2022141811A5 (https=)
RU2020109328A (ru) Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
RU2015122757A (ru) Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
RU2015118145A (ru) Замещенные бензольные соединения
RU2019100295A (ru) Соединения и композиции для подавления активности shp2
JP2015526519A5 (https=)
KR20170029495A (ko) 테트라하이드로피라닐메틸기를 갖는 피리돈 유도체
JP2019048899A (ja) 化合物及び使用方法
CA2519898A1 (en) Oral administration of cyclic protein tyrosine kinase inhibitors
CN116162087B (zh) 一种hpk 1和/或lck激酶调节剂、制备方法及其应用
JP2013503903A5 (https=)
RU2014151850A (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
AR069676A1 (es) Inhibidores de cinesina como productos terapeuticos para el cancer
US20240051937A1 (en) Isoindolinone amide compounds useful to treat diseases associated with gspt1